| Name | Title | Contact Details |
|---|
Montigen Pharmaceuticals is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Merck KGaA, Darmstadt, Germany and Pfizer Inc. in ovarian cancer. Syndax is also developing entinostat as a combination therapeutic in a Phase 3 clinical trial that is being conducted with ECOG-ACRIN for advanced hormone receptor positive breast cancer.
ATH's sales and technology groups build custom wireless turn-key technology solutions that relate to specific customer body motion measurement needs and market opportunities. ATH's vision is to commercialize it's patent portfolio and lead the industry in distributed wireless bioMotion technology and data capture processes. Founded in 2005, Applied Technology Holdings Inc., is a hardware and software maker specializing in wireless bioMotion monitoring systems for medical, sports, gaming, military and aviation applications. ATH's subsidiaries are experts in supporting the solution provider platforms for easy integration into the target markets. Other ATH companies participate in the Sports, Medical, Gaming, Aviation, and Military market opportunities and segments.
Adeona Pharmaceuticals is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Axcella is designing and developing AXA Candidates, compositions of endogenous metabolic modulators, or EMMs, engineered in distinct ratios, designed to target and maximize the fundamental role that EMMs play in regulating multiple metabolic functions. Axcella`s AXA Candidates are generated from its proprietary, human-focused AXA Development Platform. Axcella believes its expertise and capabilities in EMMs position it to become a preeminent biotechnology company reprogramming metabolism to address a diverse set of complex diseases and support health. Axcella`s AXA Development Platform has already produced a pipeline of product candidates in programs targeting liver, muscle and blood. Axcella was founded by Flagship Pioneering.